From the Guidelines
Steroids, such as prednisone, are recommended for the treatment of pleuritis, particularly in cases with significant symptoms, at a dose of 20 mg/d for 3 days. This approach is based on the management guidelines for pleural/pericardial effusion, which suggest considering a short course of steroids for patients with significant symptoms 1. The use of steroids in pleuritis aims to reduce inflammation of the pleural membranes, thereby alleviating symptoms such as chest pain and shortness of breath.
Key Considerations
- The dose of prednisone recommended is 20 mg/d for 3 days, as suggested by guidelines for managing pleural/pericardial effusion 1, 2.
- Steroids are particularly beneficial when pleuritis is caused by autoimmune conditions or when significant symptoms are present.
- It is crucial to identify and address the underlying cause of pleuritis for effective long-term management, as steroids treat the inflammation but not the primary condition.
- Patients should be monitored for potential side effects of steroid use, including increased blood sugar, mood changes, fluid retention, and increased susceptibility to infections.
Management Approach
- For acute pleuritis, a short course of steroids like prednisone can be effective in reducing inflammation and alleviating symptoms.
- The medication should be taken with food to minimize gastrointestinal side effects, and patients should follow a prescribed tapering schedule to avoid adrenal suppression.
- In cases where pleuritis is caused by an infection, steroids may be used alongside appropriate antibiotics to manage both the infection and the inflammatory response.
From the Research
Role of Steroids in Pleuritis Treatment
- The use of steroids, such as prednisone, in the treatment of pleuritis is a topic of ongoing research and debate 3, 4, 5.
- A pilot randomized clinical trial, STOPPE, found no preliminary evidence of benefits of dexamethasone in improving time to sustained normalization of vital signs in patients with community-acquired pneumonia and pleural effusion 3.
- The study also found no differences in C-reactive protein or leukocyte counts, except for a higher leukocyte count in the dexamethasone group at Day 3, and no consistent intergroup differences in radiographic pleural opacification 3.
- Another study discussed the use of steroid therapy as an adjunct and exploratory therapy in the management of pleural infection, but did not provide conclusive evidence of its effectiveness 4.
- A review of the clinical pharmacology of non-steroidal anti-inflammatory drugs (NSAIDs) noted that NSAIDs have potent anti-inflammatory, analgesic, and antipyretic activity, but are also associated with an increased risk of adverse gastrointestinal, renal, and cardiovascular effects 6.
- A recent journal club discussed the significance and limitations of trials evaluating the optimal duration of antibiotics and the usefulness of corticosteroids in the management of parapneumonic effusion and pleural infection, including the STOPPE trial 5.
Key Findings
- The STOPPE trial found no benefit from the use of dexamethasone in unselected patients with pneumonia and pleural effusion 3, 5.
- The trial suggested that shorter antibiotic courses may produce less adverse events while being equally efficacious to longer courses in a subgroup of patients with pleural infection that is stabilised with only medical treatment and does not require surgery 5.
- Further studies are required to confirm these findings and to determine the optimal duration of antibiotics and the usefulness of corticosteroids in the management of pleural infection 5.
Steroid Therapy
- Steroid therapy, such as prednisone, may be considered as an adjunct therapy in the management of pleural infection, but its effectiveness is not well established 4, 5.
- The use of steroids in pleuritis treatment should be carefully considered, taking into account the potential benefits and risks, as well as the individual patient's condition and response to treatment 3, 5.